Skip to main content
Premium Trial:

Request an Annual Quote

Squibb Licenses Genome Therapeutics' Microbial Sequence Database

Premium

PRINCETON, NJ--Bristol-Myers Squibb here has signed a licensing agreement with Waltham, Mass., based Genome Therapeutics that gives the pharmaceutical giant access to the proprietary Patho Genome microbial sequence database. The alliance will expand Squibb's initiatives in applied genomics.

Squibb will gain nonexclusive access to the PathoGenome information in exchange for annual subscription fees, milestone payments, and royalty payments on any small molecules developed as a result of the partnership. Genome Therapeutics retains rights associated with the therapeutic, diagnostic, and vaccine use of bacterial genes or gene products.

"This alliance will significantly enhance our internal efforts in the important area of infectious diseases," observed Peter Ringrose, president of Squibb's Pharmaceu tical Research Institute. Robert Hennessey, Genome Therapeutics' president, chairman, and CEO, added, "Bristol-Myers Squibb has taken aggressive steps to incorporate human genomic sequence information into its research programs. We consider this agreement, in the pathogen arena, a significant validation of the comprehensive microbial genomic information available in our PathoGenome database." PathoGenome uses proprietary bioinformatics software to create a research tool that offers sequence information from both public-domain sources and from Genome Therapeutics' own research.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.